Answers are grounded in this paper and cite their sources.
Retrospective analysis shows prolonged dual antiplatelet therapy reduces ischemic events in aneurysm patients, implying effective prevention strategies.
Background and aims Patients with unruptured intracranial aneurysms (UIAs) and comorbid coronary artery disease or cerebral infarction carry substantial vulnerability to mid-term ischemic events. This study aimed to evaluate the secondary prevention effect of different aneurysm management strategies, treating the antithrombotic exposure mandated by stent-assisted coiling (SAC) with prolonged dual antiplatelet therapy (DAPT) as the principal mechanism of interest, and assessing whether this regimen confers superior mid-term systemic ischemic protection compared with surgical clipping (SC) or simple coiling. Methods We retrospectively analyzed 1,954 consecutive UIA patients with systemic vascular risk factors. Treatment exposures were categorized into: SC (n=611, reference), simple coiling (n=338), and SAC (STENT-based, n=1,005). The primary outcome was the 6-month ischemic cardio-cerebrovascular event rate, representing mid-term systemic ischemic vulnerability under each treatment-associated antithrombotic exposure. Baseline demographics, vascular comorbidities, and aneurysm characteristics were summarized using descriptive statistics. Mid-term risk associations were evaluated using independently refitted propensity-balanced matched cohorts for treatment-specific exposure contrasts. Results Compared with the SC reference exposure, the 6-month ischemic CCVE risk was lowest under STENT-based/DAPT exposure (3.6%), followed by COIL-only exposure (9.7%), and highest under surgical clipping exposure (22.4%), demonstrating a sustained mid-term ischemic risk gradient consistent with a treatment-associated risk-modifying signal favoring prolonged DAPT exposure. Conclusions Among UIA patients with systemic cardio-cerebrovascular diseases, prolonged DAPT exposure mandated by stent-assisted coiling exhibited the strongest mid-term systemic ischemic risk reduction signal, supporting its potential role as a treatment-associated secondary prevention strategy beyond localized aneurysm exclusion alone. Conflict of interest YINGCHAO HE: nothing to disclose. YINZHOU WANG: nothing to disclose. Table 1 - belongs to Results
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: